secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001213900-25-042251
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed Q3 FY2025 net loss $2.12M, revenue $1.26M, cash $4.68M, needs financing
-----------------------------------------------------------------------------

- Net loss of $2.12M for Q3 ended Mar 31, 2025, vs $1.72M same quarter last year; loss per share $1.94.
- BayMedica revenue $1.26M (+8% YoY); gross margin declined due to pricing pressure.
- Cash and equivalents $4.68M (Jun 30, 2024: $6.57M); expects to fund operations into Q3 2025.
- R&D expenses $0.91M vs $0.65M YoY, driven by INM-901 and INM-089 programs.
- Company seeks additional financing through equity, debt, or collaborations to fund pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025042251/0001213900-25-042251-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025042251/ea0241856-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-042251

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer